Sweden
Anyo Labs, founded in 2022 and headquartered in Sweden, is at the frontier of drug discovery, leveraging the power of AI and chemistry to build the world's fastest small molecular drug discovery tools. Their tagline, “We have built the world’s fastest small molecular drug discovery tools, born in the intersection of chemistry and AI,” underscores their commitment to innovation in AI, Biotechnology, Health Care, Life Sciences, and Pharmaceutical sectors.
The company specializes in virtual screening and de novo small molecular drug generation, aiming to enhance early-stage drug discovery projects. Their software ensures unprecedented computational efficiency, revolutionizing data-efficient and cost-effective hit identification. Other features include hit-to-lead optimization and a PPI module, capable of identifying correlations between hundreds of proteins.
In September 2023, Anyo Labs secured a kr100.00K Pre Seed Round investment from Chalmers Ventures, supporting their ambitious growth plans and reinforcing their potential for transformative impact in the industry.
